70-Gene Signature

What the 70-Gene Signature Means

The 70-Gene Signature, often called MammaPrint, is a special lab test used in breast cancer care. It looks at the activity levels of 70 genes in a sample of breast cancer tissue. These genes are linked to how likely the cancer is to come back or spread after initial treatment. The test is designed for people with early-stage invasive breast cancer, meaning the cancer has started to grow beyond the milk ducts or lobules but is still relatively small (less than 5 centimeters) and has either no lymph node involvement or limited spread to 1 to 3 lymph nodes.

Why the Test Can Matter in Cancer Care

Knowing whether breast cancer is likely to return is important because it helps doctors and patients make more informed treatment decisions. If the test shows a high risk that the cancer might come back or spread, doctors may recommend chemotherapy to lower that risk. On the other hand, if the test indicates a low risk, some patients might avoid chemotherapy and its side effects. This test adds information beyond traditional factors like tumor size and hormone receptor status, helping to personalize treatment plans.

What Patients Might Experience When This Term Comes Up

Patients might hear about the 70-Gene Signature or MammaPrint during discussions about treatment options after surgery for early-stage breast cancer. The test results may be included in pathology reports or treatment planning documents. It’s common to hear about risk levels for cancer recurrence or spread based on the test. Because the test involves genetic information and risk estimates, it can feel confusing or uncertain. Patients are encouraged to ask their care team what the results mean for their specific situation and treatment choices.

How Doctors Use the 70-Gene Signature Test

Doctors mainly use this test during diagnosis and treatment planning for early-stage breast cancer. It helps provide a clearer picture of the cancer’s biology and risk of returning. The test results are combined with other clinical information to guide decisions about chemotherapy and other treatments. It is one tool among many and does not replace other important factors like tumor grade, hormone receptor status, or overall health.

Common Confusions and What the Test Does Not Mean

The 70-Gene Signature test does not guarantee what will happen with the cancer. A low-risk result does not mean the cancer will never come back, and a high-risk result does not mean it definitely will. The test is not a diagnosis or a treatment by itself but a way to estimate risk based on gene activity. It should not be the only factor deciding treatment. Understanding this helps avoid overinterpreting the results.

Questions to Ask Your Care Team

Patients may find it helpful to ask: What does my 70-Gene Signature or MammaPrint result mean for my treatment? How does it affect my chances of cancer coming back? Are there other tests or factors we should consider? How reliable is this test for my specific cancer? These questions can help patients feel more informed and involved in their care decisions.

Reading the Test Results in Context

The 70-Gene Signature test is one piece of a larger puzzle. It provides additional information that doctors use alongside other tests and clinical details. It’s important to understand the results as part of the overall treatment plan rather than alone. This helps patients and caregivers make balanced decisions with their healthcare team.

Important Safety and Next Steps

This information is educational and cannot replace personalized medical advice. Each person’s cancer and situation are unique, so treatment decisions should always be made with the guidance of a healthcare provider. If you or a loved one is offered this test, a good next step is to talk with your cancer care team about what the results could mean for your treatment plan and how they fit with other findings. This conversation can help you feel more confident and supported in your care.